DCLK1-Targeted Therapeutic Platform
Solid Tumor Cancers (Pancreatic, Colon, Kidney, Ovarian, Breast)
Pre-clinicalActive
Key Facts
Indication
Solid Tumor Cancers (Pancreatic, Colon, Kidney, Ovarian, Breast)
Phase
Pre-clinical
Status
Active
Company
About Coare Biotechnology
Coare Biotechnology is a private, pre-clinical stage company dedicated to designing and developing first-in-class anti-cancer therapeutics that target cancer stem cells responsible for metastasis, therapy resistance, and relapse. Its core technology platform is built around targeting the DCLK1 protein, which marks and drives tumorigenesis in multiple solid tumors. The company's scientific foundation originated at the University of Oklahoma Health Sciences Center and has been licensed to Coare, with development supported by non-dilutive NIH funding and collaborations with academic institutions.
View full company profile